Business Description
Ascendis Pharma A/S
NAICS : 325411
SIC : 2833
ISIN : US04351P1012
Description
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.62 | |||||
Equity-to-Asset | -0.18 | |||||
Debt-to-Equity | -4.42 | |||||
Debt-to-EBITDA | -1.62 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 3.98 | |||||
Beneish M-Score | 0.41 | |||||
WACC vs ROIC |
Growth Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 213.9 | |||||
3-Year EBITDA Growth Rate | 6.7 | |||||
3-Year EPS without NRI Growth Rate | -6.4 | |||||
3-Year FCF Growth Rate | -8.9 | |||||
Future 3-5Y Total Revenue Growth Rate | 63.35 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 25.4 | |||||
9-Day RSI | 31.94 | |||||
14-Day RSI | 36.96 | |||||
6-1 Month Momentum % | 67.39 | |||||
12-1 Month Momentum % | 84.35 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.56 | |||||
Quick Ratio | 2.5 | |||||
Cash Ratio | 2.02 | |||||
Days Inventory | 1384.62 | |||||
Days Sales Outstanding | 30.21 | |||||
Days Payable | 930.99 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.7 | |||||
Shareholder Yield % | -1.09 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 83.36 | |||||
Operating Margin % | -169.63 | |||||
Net Margin % | -179.47 | |||||
FCF Margin % | -175.03 | |||||
ROE % | -890.41 | |||||
ROA % | -52.73 | |||||
ROIC % | -168.38 | |||||
ROC (Joel Greenblatt) % | -228.55 | |||||
ROCE % | -58.7 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 27.75 | |||||
EV-to-EBIT | -17.76 | |||||
EV-to-Forward-EBIT | -14.18 | |||||
EV-to-EBITDA | -18.59 | |||||
EV-to-Forward-EBITDA | -14.94 | |||||
EV-to-Revenue | 27.93 | |||||
EV-to-Forward-Revenue | 19.29 | |||||
EV-to-FCF | -16.57 | |||||
Earnings Yield (Greenblatt) % | -5.63 | |||||
FCF Yield % | -6.52 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ASND
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Ascendis Pharma A/S Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 288.74 | ||
EPS (TTM) ($) | -9.213 | ||
Beta | 0.52 | ||
Volatility % | 54.49 | ||
14-Day RSI | 36.96 | ||
14-Day ATR ($) | 5.27162 | ||
20-Day SMA ($) | 146.284 | ||
12-1 Month Momentum % | 84.35 | ||
52-Week Range ($) | 66.03 - 161 | ||
Shares Outstanding (Mil) | 56.61 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Ascendis Pharma A/S Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Ascendis Pharma A/S Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Ascendis Pharma A/S Frequently Asked Questions
What is Ascendis Pharma A/S(ASND)'s stock price today?
When is next earnings date of Ascendis Pharma A/S(ASND)?
Does Ascendis Pharma A/S(ASND) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |